T-cell phenotypes associated with effective CAR T-cell therapy in postinduction vs relapsed multiple myeloma

T cells from patients early in myeloma therapy exhibit better fitness for CAR T manufacturing than those from relapsed/refractory patients. CAR T cells may be more effective if manufactured from patients before onset of relapsed/refractory disease.

Na minha lista:
Detalhes bibliográficos
Publicado no:Blood Adv
Main Authors: Garfall, Alfred L., Dancy, Ehren K., Cohen, Adam D., Hwang, Wei-Ting, Fraietta, Joseph A., Davis, Megan M., Levine, Bruce L., Siegel, Don L., Stadtmauer, Edward A., Vogl, Dan T., Waxman, Adam, Rapoport, Aaron P., Milone, Michael C., June, Carl H., Melenhorst, J. Joseph
Formato: Artigo
Idioma:Inglês
Publicado em: American Society of Hematology 2019
Assuntos:
Stimulus Report
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC6784521/
https://ncbi.nlm.nih.gov/pubmed/31575532
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/bloodadvances.2019000600
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados